In ‘march-in’ rights, some see a tool to lower drug prices. Others see a threat to intellectual property; Gilead’s Trodelvy fails in lung cancer

Taking stock of the drug industry, from the lab to the medicine chest

January 22, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Kayana Szymczak for STAT STAT+ | In 'march-in' rights, some see a tool to lower drug prices. Others see a threat to intellectual property White House proposal to use march-in rights to lower drug prices alarms pharma, with profits and intellectual property rights at stake. By Ed Silverman STAT+ | Gilead's Trodelvy fails in lung cancer and raises new questions on antibody drug conjugate drugs The result, from a closely watched study called Evoke-01, will be seen as a disappointment by investors and oncologists alike. By Matthew Herper STAT+ | FDA sets aggressive deadline for inspection overhaul The FDA has a huge job ahead of overhauling the way it handles inspections of regulated products, and it plans to get it done this year. By John Wilkerson Adobe Opinion: The FDA and FTC need to crack down on TikTok and Instagram influencers pitching prescription drugs Influencers with no medical training regularly use TikTok and Instagram to promote prescription drugs. It's time for more rules. By Sneha Dave and Sydney Reed and Steven Woloshin

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser